V. Ö. BARIŞ Et Al. , "How did the population characteristics of ENGAGE-AF trial transcribed real life conditions in Turkey: An external validation test with evaluation of treatment safety in patients with atrial fibrillation on edoxaban therapy in real-life in Turkey (ETNA)," Türk Kardiyoloji Derneği 38. Ulusal Kardiyoloji Kongresi , vol.26, Antalya, Turkey, pp.75-76, 2022
BARIŞ, V. Ö. Et Al. 2022. How did the population characteristics of ENGAGE-AF trial transcribed real life conditions in Turkey: An external validation test with evaluation of treatment safety in patients with atrial fibrillation on edoxaban therapy in real-life in Turkey (ETNA). Türk Kardiyoloji Derneği 38. Ulusal Kardiyoloji Kongresi , (Antalya, Turkey), 75-76.
BARIŞ, V. Ö., ERTÜRK, E., ÇETİN, N., BAKIR, E. O., ELÇİK, D., TOTAN, Ş., ... Türk, U. Ö.(2022). How did the population characteristics of ENGAGE-AF trial transcribed real life conditions in Turkey: An external validation test with evaluation of treatment safety in patients with atrial fibrillation on edoxaban therapy in real-life in Turkey (ETNA) . Türk Kardiyoloji Derneği 38. Ulusal Kardiyoloji Kongresi (pp.75-76). Antalya, Turkey
BARIŞ, VEYSEL Et Al. "How did the population characteristics of ENGAGE-AF trial transcribed real life conditions in Turkey: An external validation test with evaluation of treatment safety in patients with atrial fibrillation on edoxaban therapy in real-life in Turkey (ETNA)," Türk Kardiyoloji Derneği 38. Ulusal Kardiyoloji Kongresi, Antalya, Turkey, 2022
BARIŞ, VEYSEL Ö. Et Al. "How did the population characteristics of ENGAGE-AF trial transcribed real life conditions in Turkey: An external validation test with evaluation of treatment safety in patients with atrial fibrillation on edoxaban therapy in real-life in Turkey (ETNA)." Türk Kardiyoloji Derneği 38. Ulusal Kardiyoloji Kongresi , Antalya, Turkey, pp.75-76, 2022
BARIŞ, V. Ö. Et Al. (2022) . "How did the population characteristics of ENGAGE-AF trial transcribed real life conditions in Turkey: An external validation test with evaluation of treatment safety in patients with atrial fibrillation on edoxaban therapy in real-life in Turkey (ETNA)." Türk Kardiyoloji Derneği 38. Ulusal Kardiyoloji Kongresi , Antalya, Turkey, pp.75-76.
@conferencepaper{conferencepaper, author={VEYSEL ÖZGÜR BARIŞ Et Al. }, title={How did the population characteristics of ENGAGE-AF trial transcribed real life conditions in Turkey: An external validation test with evaluation of treatment safety in patients with atrial fibrillation on edoxaban therapy in real-life in Turkey (ETNA)}, congress name={Türk Kardiyoloji Derneği 38. Ulusal Kardiyoloji Kongresi}, city={Antalya}, country={Turkey}, year={2022}, pages={75-76} }